Endometrial Genomic Profile in Endometrial Priming

Genomic Human Endometrial Expression Profile Clinical Trial

Official title:

Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01778452
• Other study ID #: VLC18012013
• Status: Completed
• Phase: N/A
• First received: January 25, 2013
• Last updated: February 14, 2013
• Start date: November 2009
• Est. completion date: January 2013

Study information

• Verified date: February 2013
• Source: Instituto Valenciano de Infertilidad, IVI VALENCIA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Description:

We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone

• 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: January 2013
• Est. primary completion date: October 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• 6 egg healthy volunteer egg donors.

• Volunteers.

• 18-35 years old

• Healthy.

• BMI <28.

Exclusion Criteria:

• - BMI > 28

• Smokers-

Study Design

Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Genomic Human Endometrial Expression Profile

Intervention

Procedure:
• endometrial biopsy
endometrial biopsy

Locations

Country	Name	City	State
Spain	Ivi Valencia	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
Instituto Valenciano de Infertilidad, IVI VALENCIA	Igenomix

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	genetic endometrial human profile expression	implantation related genes profile expression	Oocyte donors will be followed up for four to six months	Yes